Home / ImmunoSignatures
Slide background


Researchers have been attempting to develop noninvasive, blood-based clinical diagnostics for over 100 years. Remarkably, less than 30 new biomarkers have been approved since that time. The vast majority of these tests are relatively nonspecific or insensitive and few are effective early markers. In addition, there is growing concern that regular screening with these biomarkers may do more harm than good, since the large number of false positives translates to unnecessary therapeutic interventions that carry increased risk to the patient and increased cost to the healthcare system.

Any disease that affects the immune response(autoimmune, cancer, infectious disease, metabolic and neurologic diseases) can potentially be measured using immune signature Test. The basis for this unique platform is high-density peptide array that is specially designed to query the myriad of antibodies present in a human blood sample. The fabrication of theses arrays leverages and processes similar to those used in the manufacturing of silicon-based electronics, making it scalable. Additional indications do not require a new product development process rather a new algorithm.

HealthTell’s ImmunoSignature adds value to the Clinical development process and identification of diseases in the general population. Multiple diseases are under review with partners in academia and biopharmaceuticals to assess the impact of patient stratification, patient responders and incidence of adverse events among patients.

Notable demonstration of differential disease detection is evidenced among patients with autoimmune diseases: lupus, dermatomyositis, scleroderma and rheumatoid arthritis as published at ACR, 2016. Evaluation of the ImmunoSignature suggests distinction among patients with varying disease activity for Lupus. Studies reflect our technology can identify responders and non-responders as well as adverse events. This is particularly helpful to pharmaceutical firms seeking more insight into clinical studies.